Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas

NCT03259503 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03259503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03259503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
September 13, 2019
Completion date
November 5, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent t-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory hodgkin lymphoma, refractory t-cell non-hodgkin lymphoma